Cargando…
Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma
The new era of immune-oncology has brought complexities and challenges that emphasize the need to identify new strategies and models to develop successful and cost-effective therapies. The inclusion of a canine model in the drug development of cancer immunotherapies is being widely recognized as a v...
Autores principales: | Dias, Joana N. R., André, Ana S., Aguiar, Sandra I., Gil, Solange, Tavares, Luís, Aires-da-Silva, Frederico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427286/ https://www.ncbi.nlm.nih.gov/pubmed/34513964 http://dx.doi.org/10.3389/fvets.2021.621758 |
Ejemplares similares
-
Panobinostat-loaded folate targeted liposomes as a promising drug delivery system for treatment of canine B-cell lymphoma
por: André, Ana S., et al.
Publicado: (2023) -
Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies
por: Dias, Joana N. R., et al.
Publicado: (2018) -
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018) -
Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy
por: Dias, Joana N. R., et al.
Publicado: (2022) -
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
por: Poggio, Teresa, et al.
Publicado: (2018)